[go: up one dir, main page]

SI1730303T1 - Mutacije gena pik3ca pri rakavih obolenjih pri ljudeh - Google Patents

Mutacije gena pik3ca pri rakavih obolenjih pri ljudeh

Info

Publication number
SI1730303T1
SI1730303T1 SI200531792T SI200531792T SI1730303T1 SI 1730303 T1 SI1730303 T1 SI 1730303T1 SI 200531792 T SI200531792 T SI 200531792T SI 200531792 T SI200531792 T SI 200531792T SI 1730303 T1 SI1730303 T1 SI 1730303T1
Authority
SI
Slovenia
Prior art keywords
mutations
human cancers
pik3ca gene
pik3ca
gene
Prior art date
Application number
SI200531792T
Other languages
English (en)
Inventor
Yardena Samuels
Victor Velculescu
Kenneth W. Kinzler
Bert Vogelstein
Original Assignee
The Johns-Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1730303(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Johns-Hopkins University filed Critical The Johns-Hopkins University
Publication of SI1730303T1 publication Critical patent/SI1730303T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SI200531792T 2004-03-02 2005-02-18 Mutacije gena pik3ca pri rakavih obolenjih pri ljudeh SI1730303T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54888604P 2004-03-02 2004-03-02
PCT/US2005/005193 WO2005091849A2 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers
EP05723277.9A EP1730303B1 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers

Publications (1)

Publication Number Publication Date
SI1730303T1 true SI1730303T1 (sl) 2013-12-31

Family

ID=35056655

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200531792T SI1730303T1 (sl) 2004-03-02 2005-02-18 Mutacije gena pik3ca pri rakavih obolenjih pri ljudeh
SI200532262T SI3296407T1 (sl) 2004-03-02 2005-02-18 Mutacije gena PIK3CA pri rakih pri ljudeh

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200532262T SI3296407T1 (sl) 2004-03-02 2005-02-18 Mutacije gena PIK3CA pri rakih pri ljudeh

Country Status (14)

Country Link
US (6) US8026053B2 (sl)
EP (5) EP2497836B1 (sl)
JP (10) JP2007530017A (sl)
AU (2) AU2005227148B2 (sl)
CA (1) CA2560696C (sl)
CY (1) CY1121975T1 (sl)
DK (3) DK3296407T3 (sl)
ES (5) ES2869167T3 (sl)
HU (1) HUE045690T2 (sl)
LT (1) LT3296407T (sl)
PL (2) PL1730303T3 (sl)
PT (3) PT3556866T (sl)
SI (2) SI1730303T1 (sl)
WO (1) WO2005091849A2 (sl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3556866T (pt) 2004-03-02 2021-04-30 Univ Johns Hopkins Mutações do gene de pik3ca em cancros humanos
EP1849877A1 (en) * 2006-04-24 2007-10-31 Erasmus University Medical Center Rotterdam Replicative history of T-and B-cell subsets
WO2008109375A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
GB2453173A (en) 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
EP2225376B1 (en) 2007-12-03 2014-01-08 Santaris Pharma A/S Rna antagonist compounds for the modulation of pik3ca expression
WO2009152346A2 (en) * 2008-06-11 2009-12-17 Intradigm Corporation Compositions comprising phosphoinositide 3-kinase sirna and methods of use thereof
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
ES2633111T3 (es) * 2010-03-26 2017-09-19 Hongzhi Zou Métodos y materiales para detectar neoplasia colorrectal
AU2011329180A1 (en) * 2010-11-15 2013-05-02 Enzon Pharmaceuticals, Inc. Methods of treating cancers with HER3 and PIK3CA antisense oligonucleotides
WO2012068231A1 (en) * 2010-11-16 2012-05-24 Glaxosmithkline Llc Method of administration and treatment
WO2012106175A1 (en) 2011-02-02 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma
EP2678018A4 (en) * 2011-02-23 2015-09-30 Intellikine Llc COMBINATION OF CHINESE HEMMER AND USES THEREOF
CN103748236B (zh) 2011-04-15 2018-12-25 约翰·霍普金斯大学 安全测序系统
KR20140050689A (ko) * 2011-07-28 2014-04-29 제넨테크, 인크. Pik3ca h1047r 녹-인 비인간 동물 유방암 모델
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
CN102816839A (zh) * 2012-07-06 2012-12-12 杭州艾迪康医学检验中心有限公司 用于检测结直肠癌pik3ca基因热点突变位点的试剂盒
PL2912468T3 (pl) 2012-10-29 2019-04-30 Univ Johns Hopkins Test papanicolaou pod kątem raka jajnika i endometrium
CA2899712C (en) * 2013-03-13 2021-01-05 F. Hoffmann-La Roche Ag Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene
EP4234721A3 (en) 2013-03-14 2023-10-18 Mayo Foundation for Medical Education and Research Detecting neoplasm
KR101501826B1 (ko) * 2013-04-05 2015-03-13 연세대학교 산학협력단 위암에 대한 예후 예측 모형의 제조방법
WO2015017528A1 (en) * 2013-07-30 2015-02-05 Blueprint Medicines Corporation Pik3c2g fusions
US11078539B2 (en) 2014-03-31 2021-08-03 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasm
US12391985B2 (en) 2014-08-07 2025-08-19 Pharmassist Ltd Method of determining PIK3CA mutational status in a sample
RS59710B1 (sr) 2014-08-07 2020-01-31 Pharmassist Ltd Metod određivanja mutacionog statusa pik3ca u uzorku
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
CN104531854B (zh) * 2014-11-10 2017-01-18 中国人民解放军第三〇七医院 检测西妥昔单抗治疗转移性结直肠癌耐药的试剂盒
US10030272B2 (en) 2015-02-27 2018-07-24 Mayo Foundation For Medical Education And Research Detecting gastrointestinal neoplasms
EP3274440A4 (en) 2015-03-27 2019-03-06 Exact Sciences Corporation Detecting esophageal disorders
EP4435112A3 (en) * 2015-05-27 2025-02-26 Quest Diagnostics Investments Incorporated Compositions and methods for screening solid tumors
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
KR102892240B1 (ko) 2015-08-31 2025-11-27 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 위 신생물 검출 방법
EP3383391A1 (en) 2015-12-03 2018-10-10 Novartis AG Treatment of cancer with a pi3k inhibitor in a patient preselected for having a pik3ca mutation in the ctdna
RU2608960C1 (ru) * 2016-03-18 2017-01-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "РОНЦ им. Н.Н. Блохина" Минздрава России) Клеточная линия crov Cel муцинозного рака яичников человека, предназначенная для разработки лечения таргетными препаратами
CN109153993B (zh) 2016-04-14 2023-02-17 梅约医学教育与研究基金会 检测胰腺高度异型增生
US10370726B2 (en) 2016-04-14 2019-08-06 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasia
AU2018229294B2 (en) 2017-02-28 2024-06-13 Exact Sciences Corporation Detecting prostate cancer
EP3604521A4 (en) * 2017-03-30 2021-05-19 The University of Tokyo MULTIPLE GENES OF DIFFERENT INTEREST EVALUATION PROCESS
MX2020001575A (es) 2017-08-07 2020-11-18 Univ Johns Hopkins Materiales y métodos para evaluar y tratar el cáncer.
JP7067896B2 (ja) 2017-10-27 2022-05-16 シスメックス株式会社 品質評価方法、品質評価装置、プログラム、および記録媒体
CN111655869B (zh) 2017-11-30 2024-06-28 梅约医学教育与研究基金会 检测乳腺癌
US20220073977A1 (en) 2020-02-14 2022-03-10 The Johns Hopkins University Methods and materials for assessing nucleic acids
CN111363827A (zh) * 2020-04-30 2020-07-03 北京和合医学诊断技术股份有限公司 用于检测pik3ca基因突变的引物组及其应用方法
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff
CN116219015A (zh) * 2023-02-06 2023-06-06 中日友好医院(中日友好临床医学研究所) 基于pcr的dna中pik3ca基因突变检测试剂盒及检测方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248671A (en) * 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) * 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5846624A (en) * 1996-12-06 1998-12-08 The Standard Register Company Dual face pressure sensitive label
US7670767B1 (en) * 1997-01-16 2010-03-02 The Regents Of The University Of California Genetic alterations associated with cancer
US6277563B1 (en) 1997-01-16 2001-08-21 The Regents Of The University Of California Genetic alterations associated with cancer
US6558903B1 (en) 1999-06-30 2003-05-06 Millennium Pharmaceuticals, Inc. Kinases and uses thereof
ES2302699T3 (es) 1999-08-27 2008-08-01 Novartis Vaccines And Diagnostics, Inc. Oligonucleotidos quimericos antisentido y formulaciones de transfeccion celular de los mismos.
CA2393002A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2002027028A1 (en) * 2000-09-28 2002-04-04 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
US20020142305A1 (en) 2001-03-27 2002-10-03 Koei Chin Methods for diagnosing and monitoring ovarian cancer by screening gene copy numbers
US20030135033A1 (en) * 2002-01-04 2003-07-17 Anke Klippel-Giese Compounds and methods for the identification and/ or validation of a target
EP1539041A1 (en) 2002-07-25 2005-06-15 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
CA2518916A1 (en) * 2003-04-03 2004-10-21 Joseph R. Garlich Pi-3 kinase inhibitor prodrugs
PT3556866T (pt) 2004-03-02 2021-04-30 Univ Johns Hopkins Mutações do gene de pik3ca em cancros humanos

Also Published As

Publication number Publication date
JP2018023400A (ja) 2018-02-15
JP7304987B2 (ja) 2023-07-07
JP5336620B2 (ja) 2013-11-06
US8026053B2 (en) 2011-09-27
LT3296407T (lt) 2019-09-10
ES2537633T3 (es) 2015-06-10
DK1730303T3 (da) 2013-11-04
PL3296407T3 (pl) 2019-11-29
US20110319477A1 (en) 2011-12-29
JP6395917B2 (ja) 2018-09-26
ES2437590T3 (es) 2014-01-13
HUE045690T2 (hu) 2020-01-28
AU2005227148B2 (en) 2010-11-11
ES2869167T8 (es) 2022-01-20
JP2013226141A (ja) 2013-11-07
US11549150B2 (en) 2023-01-10
US20180119231A1 (en) 2018-05-03
EP3296407B1 (en) 2019-05-22
ES2869167T3 (es) 2021-10-25
PT1730303E (pt) 2013-10-31
WO2005091849A3 (en) 2009-04-16
JP7001735B2 (ja) 2022-02-10
WO2005091849A2 (en) 2005-10-06
ES2663248T3 (es) 2018-04-11
US10422006B2 (en) 2019-09-24
EP1730303A2 (en) 2006-12-13
PL1730303T3 (pl) 2014-04-30
DK3296407T3 (da) 2019-08-19
EP2497836A1 (en) 2012-09-12
SI3296407T1 (sl) 2019-09-30
AU2011200600B2 (en) 2012-02-23
EP3556866A1 (en) 2019-10-23
AU2005227148A1 (en) 2005-10-06
CY1121975T1 (el) 2020-10-14
EP2896703A3 (en) 2015-10-21
JP2018153189A (ja) 2018-10-04
PT3296407T (pt) 2019-08-23
JP2007530017A (ja) 2007-11-01
JP2022059046A (ja) 2022-04-12
EP2896703B1 (en) 2017-10-25
JP2020092711A (ja) 2020-06-18
CA2560696C (en) 2019-06-25
US20090208505A1 (en) 2009-08-20
JP7169315B2 (ja) 2022-11-10
EP3296407A1 (en) 2018-03-21
ES2743125T3 (es) 2020-02-18
JP2016041078A (ja) 2016-03-31
JP6250017B2 (ja) 2017-12-20
JP6694543B2 (ja) 2020-05-13
EP3556866B1 (en) 2021-04-07
JP2012183065A (ja) 2012-09-27
EP2497836B1 (en) 2015-01-14
CA2560696A1 (en) 2005-10-06
JP5894110B2 (ja) 2016-03-23
JP2020115891A (ja) 2020-08-06
US10704105B2 (en) 2020-07-07
JP2020028300A (ja) 2020-02-27
DK3556866T3 (da) 2021-05-03
EP1730303A4 (en) 2009-09-09
US20150079593A1 (en) 2015-03-19
US20200248275A1 (en) 2020-08-06
EP2896703A2 (en) 2015-07-22
US10787713B2 (en) 2020-09-29
PT3556866T (pt) 2021-04-30
JP6695381B2 (ja) 2020-05-20
AU2011200600A1 (en) 2011-03-10
EP1730303B1 (en) 2013-07-31
US20200024671A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
SI1730303T1 (sl) Mutacije gena pik3ca pri rakavih obolenjih pri ljudeh
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
IL177847A0 (en) Use of lipid conjugates in the treatment of disease
IL182652A0 (en) Nitrobenzindoles and their use in cancer therapy
IL172316A0 (en) Novel compounds and their use in therapy
GB0418328D0 (en) Cancer methods and medicaments
IL173576A0 (en) Use of polypeptides of the cupredoxin family in cancer therapy
EP1747284A4 (en) DIAGNOSTICS AND THERAPEUTICS OF CANCER
IL212215A0 (en) Use of lipid conjugates in the treatment of disease
TWI368509B (en) Antituberculous therapeutic drugs and kit containing the same
PT1803456E (pt) Composições farmacêuticas que compreendem l-733060 para utilização no tratamento de tumores cancerígenos
LT2340872T (lt) Naujos farmacinės kompozicijos, naudingos nemigos gydyme
GB0326578D0 (en) Cancer diagnosis and therapy
IL185575A0 (en) Benzoxazocines and their therapeutic use
GB2424794B (en) Improvements in the use of pre-configuration
IL229981A0 (en) Use of fatty conjugates to treat diseases
IL229980A0 (en) Use of fatty conjugates to treat diseases
IL229982A0 (en) Use of fatty conjugates to treat diseases
GB0423423D0 (en) Improvements in the design of toothbrushes
IL165485A0 (en) Use of osteoprotegerin in the preparation of medicaments
GB0415988D0 (en) ESR1 and cervical cancer
GB0406666D0 (en) Blush
GB0424871D0 (en) Antibodies and their use in therapy